ADOPT 2016 will give you access to the very latest clinical implement best practice to enhance genetic engineering of cells. Whether adopting an allogeneic or autologous model, define your bioprocessing and logistics needs to ensure global commercial viability of your adoptive cell immunotherapy pipeline. Scientific and business leaders from pharma, biotech, academia and the wider service community will come together to forge a roadmap for emerging genetically engineered cell immunotherapies.
Expert speakers include:
For more information and to register, click here